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Abstract
Vasculogenic mimicry (VM) is a blood supply system independent of endothelial vessels in tumor cells from
different origins. It reflects the plasticity of aggressive tumor cells that express vascular cell markers and line
tumor vasculature. The presence of VM is associated with a high tumor grade, short survival, invasion and metastasis.
Endothelial cells (ECs) express various members of the cadherin superfamily, in particular vascular endothelial
(VE-) cadherin, which is the main adhesion receptor of endothelial adherent junctions. Aberrant extra-vascular
expression of VE-cadherin has been observed in certain cancer types associated with VM. In this review we focus on
non-endothelial VE-cadherin as a prominent factor involved in the acquisition of tubules-like structures by aggressive
tumor cells and we summarize the specific signaling pathways, the association with trans-differentiation and stem-like
phenotype and the therapeutic opportunities derived from the in-depth knowledge of the peculiarities of the biology
of VE-cadherin and other key components of VM.
Background
Solid tumors require blood vessels for growth, and
access to oxygen and nutrients and anti-angiogenic ther-
apies are designed to target vascular ECs to form tumor
blood vessels. Whereas numerous preclinical models have
recognized the efficient use of angiogenesis inhibitors to
limit tumor growth, collectively only a growth delay has
been achieved in the clinic [1]. This is in part due to the
fact that tumor vasculature is more complex than
expected and alternative mechanisms for re-vascularization
might be taking place. A large number of studies in path-
ology have described a high degree of plasticity associated
with aggressive cancer. In 1999, Maniotis et al. [2] pre-
sented a new interpretation of previous findings describing
cancer cells covering non-endothelial vascular channels that
contained red blood cells. This was the initial report defin-
ing tumor cell VM as the de novo formation of perfusable,
matrix rich, vasculogenic-like network in 3D matrix in
vitro, which resembled the matrix-rich network observed in
aggressive tumors in patients [3]. The initial morphological,
clinical and molecular characterization of VM was per-
formed using human melanoma as a model. In addition to
melanoma, vasculogenic mimicry (VM) has also been
characterized in carcinomas of lung, prostate, bladder,
kidney, ovary and breast, sarcomas and gliomas. Kaplan-
Meier survival analyses indicated that patients with VM in
their tumors have a poor clinical outcome compared with
patients with tumors that do not exhibit VM. Table 1 shows
the main differences at molecular level between blood
vessels and VM networks.
The distinctive pattern of VM networks appears to
recapitulate embryonic vasculogenesis patterns and this
resemblance suggests that aggressive tumor cells convert
to an undifferentiated, embryonic-like phenotype. Gene
expression analysis demonstrated that aggressive mela-
nomas capable of VM express genes associated with
multiple cellular phenotypes, including characteristics of
epithelial cells, endothelial cells and fibroblasts [4, 5].
However, the different molecular mechanisms that
generate VM are still unclear. One of the most conspicu-
ous molecular determinants in the acquisition of VM
capabilities is the expression of the endothelial cell
marker VE-cadherin. In the current review, we focus on
the connection between VE-cadherin and its conse-
quences in the gain of the VM phenotype which is also
associated with cell plasticity and trans-differentiation of
cancer stem cells present in VM.
* Correspondence: joliver@ipb.csic.es
1IPBLN, CSIC, CIBERONC, Granada, Spain
3IPBLN, CSIC, Av. Conocimiento s/n, 18016, Granada, Spain
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Delgado-Bellido et al. Molecular Cancer  (2017) 16:65 
DOI 10.1186/s12943-017-0631-x
VE-cadherin in VM
VE-cadherin, Notch or hypoxia-inducible factor 1-α
(HIF1-α) are among the most relevant signaling mole-
cules involved in the three leading pathways that control
VM: vascular, hypoxia and embryonic/stem cell signaling
pathways. All these pathways are complex and intercon-
nected, with a large number of different molecules
performing together and modulating the outcome effect
in a different way (reviewed in [6–9]) (Fig. 1).
VE-cadherin is a trans-membrane protein commonly
expressed in endothelium, where it is responsible for
cell-cell adhesion [10]. Although VE-cadherin used to be
considered specific for ECs, its expression has been
strongly associated with aggressiveness and VM in
melanoma. Surprisingly, VE-cadherin can be found in
highly aggressive tumor cells but not in non-aggressive
ones. Moreover, its down-regulation in melanoma
implied the loss of VM formation [11].
VE-cadherin is the best known cadherin in the context
of vascular adhesion but the insights of its role in VM in
aggressive tumor cells are only beginning to be well
understood. The fact that VE-cadherin is key to under-
stand VM was discovered by Hendrix and col in 2001
[12]. In this seminal study, they showed that VE-cad-
herin is expressed in aggressive melanoma cells while its
knockdown prevented VM. On the other hand, in vivo
experimental models also demonstrated that mice defi-
cient in VE-cadherin die by severe vascular defects [13].
The reason for the expression of VE-cadherin in non-
endothelial cells is mostly unclear, but in hepatocellular
carcinoma (HCC) it may be due the to nuclear
localization of Twist1. This transcription factor has been
shown to bind VE-cadherin promoter, enhancing its ac-
tivity [14]. In melanoma, VE-cadherin expression has
been related with the activation of the Nodal/Notch
pathway [15, 16] and hypoxia-inducible factors [17, 18].
Finally, it has been suggested that human epidermal
growth factor receptor 2 (HER2) up-regulates VE-
cadherin in breast cancer cells [19].
Structurally, VE-cadherin has five extracellular calcium
domains (ECD:aa46-aa599) that can form cis-homodimers
with other VE-cadherin or similar dimers in trans-
through ECDI-ECDIV, that present on adjoining cells to
support cell-to-cell recognition and adhesion. ECDV is
required for binding to VE-PTP. VE-cadherin also has a
trans-membrane domain (TMD: aa600-aa620) and an
intracellular domain involved in post-translational
modifications (PTM) (Fig. 2). In fact, 13 possible resi-
dues of VE-cadherin that can be phosphorylated in
humans (Uniprot KB/Phosphosite Plus) have been
described but the most relevant ones, and also the
most studied, are residues Y658, S665, Y685 and
Y731. Phosphorylation in S665 of VE-cadherin takes
place through serine/threonine kinase P21 protein
(Cdc42/Rac)-activated kinase 1 (PAK) in response to
VEGF that also promotes clathrin-dependent internal-
ization of VE-cadherin [20]. Recent studies have
shown that Y658 residue is a target of focal adhesion
kinase (FAK) in tumor-associated endothelial cells,
and identify FAK as a key regulator of endothelial cell
barrier function controlling tumor metastasis [21].
Tyrosine phosphorylation of VE-cadherin Y685 causes
its internalization mediated by Src, thus playing an
important role in in vivo vascular permeability [22, 23]. In
contrast, mice expressing Y731F VE-cadherin mutant
display deficient neutrophil-extravasation; indeed, phos-
phorylation of Y731 is induced through inflammatory
mediators, such as histamine, that promote neutrophil-
extravasation [23] (see Fig. 2).
Vascular endothelial growth factor A (VEGF-A) is
known to contribute to endothelial cell proliferation,
including tumor-induced angiogenesis, and has been
associated to VM in ovarian carcinoma and melan-
oma [8]. In fact, in ovarian cancer cells VEGF-A may
up-regulate most of the signaling molecules in the
VE-cadherin signaling cascade: VE-cadherin itself,
Epithelial cell kinase (EphA2) and MMP-2 [7]. We
will analyze below different key pathways and mol-
ecules involved in VM and their connection with
VE-cadherin.
Table 1 Differences in tumor-VM and ECs-dependent angiogenesis
and VM inducer and suppressor molecules
Normal endothelial cells Vasculogenic mimicry cells
Similarities
VE-cadherin positive
E-selectin positive
CD34 positive
Differences
TIE-2 positive TIE-2 negative
VEGFR-1, 2 positive VEGFR-1, 2 negative
P-selectin positive P-selectin negative
VCAM-1/CD106 positive VCAM-1/CD106 negative
CD31/PECAM-1 positive CD31/PECAM-1 negative *13
(Subpopulations PECAM-1 positive
melanoma cells)
TIE-1 negative TIE-1 positive
VEGF-C negative VEGF-C positive
Neuropilin 1 negative Neuropilin 1 positive
Endoglin negative Endoglin positive
Tissue factor pathway inhibitor
1 (TFPI1) negative
Tissue factor pathway inhibitor 1
(TFPI1) positive
Laminin 5 gamma 2 chain
(LAMC2) negative
Laminin 5 gamma 2 chain
(LAMC2) positive
EphA-2 negative EphA-2 positive
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VE-cadherin-dependent and independent
signaling in VM
Vascular endothelial growth factor (VEGF) signaling
When we refer to VE-cadherin it is necessary to describe
VEGF receptors (VEGFRs) because they represent the
most important pathway to regulate VE-cadherin function
and turn-over. VEGFR-2 (flk-1/KDR) and VEGFR-1 (FLT-1)
are the most important receptors in this pathway although
at least five different VEGF isoforms are also known in
human. These receptors are stimulated by vascular
endothelial growth factor (VEGF-A) and represent a
crucial regulatory system of endothelial growth in a
Fig. 2 Structural features of VE-cadherin and implication in signalling. Further details are given in the text for the VE-cadherin subheading
Fig. 1 Main signaling pathways involved in vasculogenic mimicry. In vascular signaling (purple), VE-cadherin, EphA2 and VEGF lead to proteolytic
cleavage of laminin 5 and release of pro-migratory γ2x and γ2’ fragments in the extracellular matrix. Galectin 3 supports the vascular pathway,
since it enhances the expression of VE-cadherin. Stem cell signaling (blue), controlled by Notch and Nodal, up-regulates genes for pluripotency
and de-differentiation. Hypoxia (green) contributes to all previous pathways by mediating expression of some crucial signaling molecules. Finally,
Wnt proteins may promote vasculogenic mimicry through the activation of PKC and PI3K signaling, though it could play a role in tumor suppression
in certain cases
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normal cell physiology context; in contrast VEGF is
also an endothelial-specific mitogen and potent acti-
vator of vascular permeability secreted by tumor cells
[24]. VEGFR-2 is highly expressed in vascular ECs
thus forming the primitive tubular vessels called vas-
culogenesis. In contrast, VEGFR-1 is also highly
expressed in tumor cells with capacity to form VM;
this is the case of malignant melanoma [25]. As men-
tioned above, VEGF-A promotes vascular permeability
by weakening adherent junctions and tight junctions,
resulting in transient opening of the endothelial cell-
cell contacts [26]. In fact, VEGF-A promotes tyrosine
phosphorylation of VE-cadherin and its binding to
the partner β-catenin, plakoglobin and p120, via Src-
dependent mechanism [27]. VE-cadherin is inhibited
following its phosphorylation in mice deficient in Src
[27]. VE-cadherin may also be associated with and
inhibit VEGFR-2 phosphorylation and subsequent
internalization [28]. This association promotes the
phosphorylation of components of the adherent junc-
tions by Src, thus impairing the integrity of the endo-
thelial barrier and promoting tumor cell extravasation
and diffusion in pathological models [29]. In addition,
VEGF-A mediates phosphorylation of VE-cadherin in-
ternalization through sequential activation of Src, the
nucleotide exchange factor of Vav2, Rho GTPase Rac,
leading to a downstream effect on the serine/threo-
nine kinase P21 protein (Cdc42/Rac)-activated kinase
1 (PAK). Finally, phosphorylated PAK phosphorylates
VE-cadherin, triggering their internalization [26].
Moreover, VEGF signaling reduces the association be-
tween VE-cadherin and p120-catenin promoting
clathrin-dependent VE-cadherin endocytosis [30];
binding of p120 to VE-cadherin prevents its internal-
ization, while p120 silencing leads to degradation of
VE-cadherin, and loss of cell-cell contacts [30].
VEGF binding to VEGFR-1 can enhance other variety
of signaling pathways. Activation of tyrosine kinase Src
and extracellular regulatory kinases 1 and 2 (ERK1/2)
leads to cancer cell invasion and migration. In melan-
oma, VEGFR-1 seems to promote VM via PI3K/PKC
pathway. VEGFR-1 also mediates angiogenesis through
activation of PI3K/Akt pathway [7, 8]. Apart from this,
VEGFR-1 is necessary for the expression of VE-cadherin
[25]. As for VEGFR-3, it has been proved in melanoma
that endothelin-1 (ET-1) can enhance its expression and
also the expression of its ligands VEGF-C and -D. The
signaling pathway involves ET-1 binding to its receptor
ETBR, which activates hypoxia-inducible factors. The
binding also leads to phosphorylation of VEGFR-3
(probably mediated by Src and β-arrestin-1), which
becomes able to trigger the activation of MAPK signal-
ing cascade. All of these events lead finally to the
promotion of cell migration and VM [31].
Different evidences support the fact that VEGF expres-
sion is determined by EphA2 in breast cancer and
pancreatic islet carcinoma cells. Cyclooxygenase-2
(COX-2) also stimulates the expression of VEGF in other
tumor cell lines [7–9].
Cyclooxygenase-2 catalyzes the reaction that converts
arachidonic acid into primarily prostaglandin E2 (PGE2).
This molecule binds to prostanoid receptors (EP1-4) that
activate protein kinase C (PKC) and epidermal growth fac-
tor receptor (EGFR) signaling pathways. Both of them lead
to decreased apoptosis and increased tumor proliferation,
invasion and angiogenesis. In particular, PKC signaling
up-regulates VEGF expression [7–9]. In breast cancer,
elevated COX-2 expression results in the increased ability
to form VM networks, while its knockdown leads to a
reduced VM. Importantly, VM capability of breast cancer
cells with low COX-2 can be restored if PGE2 is added to
the culture [32]. It has been reported that EP3, but not
EP4, modulates VM in breast cancer [33].
On the contrary, VEGF/VEGFR-1 signaling can be
inhibited by the pigment epithelium-derived factor
(PEDF), a glycoprotein that belongs to the family of
serine protease inhibitors. Furthermore, PEDF induces
tumor cell differentiation and apoptosis, yet probably
prevents VM development, since it is usually down-
regulated in aggressive tumor cells. Even more, PEDF
silencing favors VM in melanoma [7, 8].
Tissue factor (TF) and TF pathway inhibitors (TFPI-1/2)
are involved in VM as well. Specifically, knockdown of
TFPI2 inhibited MMP-2 activity, suggesting a role for
TFPI2 in extracellular matrix remodeling associated with
VM channel formation [7, 8].
Finally, an opposite role of VEGF signaling in VM has
been proposed too. All the evidence presented so far
indicates that VEGF promotes VM, but it has been
suggested that, on the contrary, VM might increase in
the absence of this signaling pathway: VEGF would
promote angiogenesis, while VEGF blockade could
enhance some other strategies for tumor cell survival,
including VM [34].
VE-cadherin and EphA2 in VM
EphA2 has also been shown to be related to VM. EphA2
is a protein tyrosine kinase whose phosphorylation and
activity depend on the binding of ephrin-A1, although it
has been reported that EphA2 can also be constitutively
active in some tumor cells [35]. As VE-cadherin, EphA2
was found to be expressed only in highly aggressive
tumors, where it was tyrosine-phosphorylated. When
cells were cultured on a three-dimensional matrix and
labeled with anti-phosphotyrosine antibodies, the stain-
ing showed that tyrosine-phosphorylation was present
mainly in the areas of tubular network formation.
General inhibitors of protein tyrosine kinases as well as
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specific silencing of EphA2 hindered the development of
vascular networks, suggesting a potential role for phosphor-
ylated EphA2 in this process [35]. In VM, VE-cadherin and
EphA2 co-localize at the plasma membrane, specifically in
cell-to-cell contact regions. Knockdown of VE-cadherin re-
sulted in a reorganization of EphA2 location, which seemed
to move into the cytoplasm. Moreover, there was a decrease
in EphA2 phosphorylation. On account of these results, it
seems that VE-cadherin may help EphA2 translocate to the
plasma membrane, [36, 37].
PI3K up-regulates both the activity and expression of
matrix metalloproteinase-14 (MMP-14) in highly aggres-
sive cells. MMP-14 in turn activates MMP-2, and finally
cleaves laminin 5γ2 chain to produce the γ2’ and γ2x
fragments, which are secreted to the extracellular matrix
to promote migration in various tumor cell types, like
breast, colon carcinomas and hepatoma [38]. More
precisely, they activate the secretion of γ2’ and γ2x pro-
migratory fragments leading to VM in melanoma, gall-
bladder and ovarian carcinomas [39–41]. Furthermore,
poorly aggressive melanoma cells (which cannot normally
engage in VM) could form vasculogenic-like networks when
seeded on collagen gels that had been pre-conditioned by
highly aggressive melanoma cells. Aggressive cells were re-
moved before apparent formation of tubular networks, but
the examination of the a-cellular matrices showed the pres-
ence of laminin-positive patterned networks. If these matri-
ces where treated with antibodies anti-laminin-5γ2 chain
before seeding the poorly aggressive melanoma cells, they
could no longer develop tubular networks. Altogether, these
results confer great importance to this signaling cascade
and laminin-5γ2 in particular.
As for FAK, over-expression of EphA2 caused an
increase of MMP-2 in a way dependent on FAK [42].
FAK itself is highly phosphorylated at positions Y397
and Y576 in highly aggressive melanoma, but not in
poorly aggressive melanoma cells; this post-translational
changes are indicative of a fully active FAK. FAK-related
non-kinase (FRNK) can interact with focal adhesion
proteins but it lacks kinase activity, so it is considered a
dominant-negative FAK protein. Expression of FRNK
in aggressive melanoma decreased invasiveness, mi-
gration and ability to form tubular networks on colla-
gen gels. It also reduced the levels of phosphorylated
ERK1/2, whose inhibition decreased the levels of
urokinase as well as the activity of MMP-14 and
MMP-2. These results hint at a signaling cascade
where EphA2 promotes VM via FAK and ERK,
meeting the PI3K pathway at MMP-14 and leading
henceforth to the cleavage of laminin-5γ2 [43].
Notch/Nodal
Nodal/Notch belongs to the superfamily of the trans-
forming growth factor β (TGF-β). It is essential during
embryonic development, since it maintains undifferenti-
ated status of embryonic stem cells in order to ensure
growth and development. Notch is a trans-membrane
receptor with four different isoforms (Notch1-4), all of
which undergo cleavage by γ-secretase after binding of
one out of five possible ligands: Delta-like-1/3/4 and
Jagged1/2. Notch intracellular domain (NICD) is
released into the cytoplasm and it is imported to the
nucleus, where it regulates gene expression, including
expression of Nodal. Notch signaling pathway is involved
in differentiation, although cell fate depends on cellular
context. Also Notch is associated with the development
of vascular networks in embryonic stages, so it may have
a relationship with VM in cancer. Nodal binds several
membrane receptors (Cripto-1, activing-like kinase
receptors (ALK4/7), ActRIIB, and/or TGF-β receptor I
and II), causing phosphorylation of SMAD2/3, enab-
ling its association with SMAD4 and their transloca-
tion to the nucleus to activate the expression of
Nodal target genes, including LEFTY, which is
responsible of negative feedback in this signaling
pathway, as it directly inhibits Nodal.
It has been reported that disruption of the Notch
signaling cascade with γ-secretase inhibitors stabilizes
VM networks in melanoma, that is, Notch might have
an attenuating effect in VM [44]. Nevertheless, there are
evidences supporting a positive relationship between
Notch and VM: Notch-4 was shown to be highly
expressed in several aggressive melanoma cell lines
capable of VM, where it seemed to play a crucial role in
the up-regulation of Nodal expression as well. Further-
more, antibody-mediated blocking of Notch signaling
resulted in an impairment of VM ability, which could be
restored with the addition of Nodal [45]. Nodal expres-
sion normally stops after cell differentiation during
human development, but it can be rescued in tumor
cells, for instance, melanoma and breast cancer cells.
This pathway is related to tumor progression, aggressive-
ness, VM and VE-cadherin expression in aggressive
melanoma cells [15, 16].
Hypoxia
Oxygen depletion is a common situation in growing
tumors; therefore tumor cell survival and, consequently,
malignancy are often dependent on their adaptation to
hypoxia. Hypoxia-inducible factors (HIFs) and hypoxia
responsive elements (HRE) play a crucial role in this
context; HIFs are transcription factors stable in hypoxic
conditions, while HRE are the genomic regions
where HIF bind to mediate gene expression. These
transcription factors are stabilized during conditions
of hypoxia and they are critical to induce genes for
tumor cell adaption to a hostile and changing
microenvironment.
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Notably, some potential hypoxia target genes contain-
ing HRE are involved in VM, such as VEGF-A, VEGFR-
1, EphA2, Twist, Nodal, COX-2 and VE-cadherin [8, 46].
The later has been found to contain up to six HRE
upstream of the promoter [6]. As a result, hypoxia
has been reported to promote VM in a wide variety
of tumor cell lines [47–49]. In murine models of mel-
anoma, VM development in conditions of ischemia
was significantly increased. Moreover, there is a posi-
tive relationship between expression of HIF-1α and
VEGF in ischemic tumor cells [50]. Instead of VEGF,
in human fibrosarcoma, HIF-1α promoted VM by up-
regulating Neuropilin-1 (NRP-1), a VEGF receptor
and co-receptor of VEGFR-2. Unexpectedly, silencing
of NRP-1 completely disrupted tumor formation in
fibrosarcoma [51].
In human melanoma, hypoxia induced over-expression
of anti-apoptotic protein B-cell lymphoma 2 (Bcl-2),
which in turn increased VE-cadherin expression [17].
VE-cadherin was also up-regulated by HIF-1α in esopha-
geal carcinoma [18]. To summarize, hypoxia is an essen-
tial trigger for vascular signaling pathways in the process
of vasculogenic mimicry. Hypoxia may also influence
VM through BNIP3, a protein that belongs to the
family of Bcl-2. Expression of BNIP3 is remarkably
up-regulated under hypoxia, allowing its contribution
to cell migration and VM development in melanoma.
BNIP3 enhanced these processes by modulating the
organization of the actin cytoskeleton while BNIP3
knockdown completely inhibits VM, changed cell size
and shape, driving to formation of actin stress fibers,
and reduced tight and adherents junctions [52].
In glioblastoma, HIF-1α expression is mediated by
mammalian target of rapamycin (mTOR). Specific inhib-
ition or silencing of mTOR disrupted VM formation,
especially under hypoxia but also in normoxic condi-
tions, since some VM signaling molecules (HIF-1α,
MMP-2 and MMP-14) were down-regulated [47]. In
2007, A. Le Bras and col [53] showed that the expression
of VE-cadherin is controlled and regulated by a basal,
non-endothelial specific promoter, containing six puta-
tive hypoxia responsive elements (HRE) which are bind-
ing sites for HIF-1α and HIF-2α. Consistent with this,
HIF-2α (but not HIF-1α) regulated the expression of
VE-cadherin in hypoxia as well as in normoxia. HIF-1α
also induced the expression of VE-cadherin and modu-
lated VM in esophageal carcinoma cells [18]. Following
knockdown of HIF-1αVM in inhibited and the expres-
sion of VM-related genes reduced, for example EphA2,
VE-cadherin or laminin-5γ2 but not MMP-2 in vitro
and also in vivo [18]. Finally, it should be noted that
mediating gene expression is not the only way by which
hypoxia can influence VM: HIF-1α is known to stabilize
NICD [54], whose role was explained above.
Galectin-3
Galectins are carbohydrate-binding proteins whose func-
tions include cell adhesion and migration [9]. Galectin-3
(Gal-3) was proven to have oncogenic and angiogenic
properties, being up-regulated, for example, in meta-
static melanoma and breast cancer cells. Gal-3 silencing
reduced invasiveness and inhibited VM formation in
melanoma through down-regulation of the expression of
some endothelial markers, such as VE-cadherin, together
with the release of interleukin-8 (IL-8) was found to de-
crease. IL-8 is pro-angiogenic interleukin which modu-
lates the expression of MMP-2, whose important role in
VM was mentioned above [55]. Gal-3 mediates gene ex-
pression by inhibiting early growth response protein 1
(EGR-1), which loses its ability to bind (and thereby to
repress) VE-cadherin and IL-8 promoter regions [55].
Therefore, the presence of Gal-3 allows the transcription
of EGR-1 target genes. Consistent with this, gene expres-
sion microarrays analysis after silencing Gal-3 showed
that Gal-3 regulates the expression of multiple genes,
and has a negative influence on endothelial markers
aberrantly expressed in highly aggressive melanoma cells
such as VE-cadherin, IL-8, fibronectin-1, endothelial
differentiation sphingolipid G-protein receptor-1 and
MMP-2 [56]. It has been shown that shRNA of Gal-3
decreased VE-cadherin, and IL-8 promoter activity due
to enhanced transcription of factor early growth
response-1 (EGR-1) [57].
Wnt family
The Wingless (Wnt) family proteins is related to a large
range of physiological processes, including embryonic
patterning, cell proliferation, migration, cell differenti-
ation. It plays an important role in endothelial cell differ-
entiation, vascular development and angiogenesis [58],
especially Wnt5a, a member of the non-canonical Wnt
signaling. However, the role of Wnt5a in cancer is still
being debated: in certain settings has been described as
a tumor suppressor, but it is generally involved as a
pro-metastatic factor [59].
Wnt5a is known to promote cell migration by modulat-
ing several proteins of the cytoskeleton, providing tumor
cells with abilities in relocation. Moreover, Wnt5a releases
intracellular calcium, activating calcium-dependent pro-
teins such as protein kinase C (PKC), which is essential
for invasion in cancer cells. All these properties, among
others, suggest that Wnt5a is a cancer-promoting
molecule [60]. PKCα has been shown to be involved with
Wnt5a in EMT and VM in ovarian cancer cells, where the
expression of Wnt5a and PKCα were correlated and PI3K
levels were enhanced upon up-regulation of Wnt5a [61].
Over-expression of Wnt5a mediates VM formation in
ovarian cancer and lung cancer [62, 63]. In 2015, Lisha Qi
et al. [62] reported that Wnt3a expression in HT29 colon
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cancer cells promoted the capacity to form tube-like
structures and increased the levels of proteins involved in
VM such as VEGFR-2 and VE-cadherin. In addition, the
antagonist Dickkopf-1(Dkk-1) reverted the capacity to
form VM and decreased the expression of VEGFR2 and
VE-cadherin in Wnt3a-overexpressing cells.
On the other hand, Wnt5a may perform as a tumor
suppressor in certain cancers by inhibiting β-catenin-
mediated transcription via several different molecules,
preventing the expression of potential oncogenes. For
this reason, the opposing effects of Wnt proteins re-
main controversial [60].
Epithelial Mesenchymal Transition (EMT) in VM
EMT is a dynamic biological process where polarized
epithelial cells lose their epithelial properties and gain
typical characteristics of mesenchymal cells [64]. The
best known regulator of EMT is Transforming Growth
Factor-beta (TGF-β), whose role in EMT is well-
established [64, 65]. In 2008, Myriam Labelle and col
[66] showed that VE-cadherin is induced in EMT in
mammary tumor cells and it is also aberrantly expressed
in invasive human breast carcinomas. In addition,
VE-cadherin influenced the levels of SMAD2 phosphor-
ylation and the expression of TGF-target genes. Thus,
VE-cadherin might promote tumor progression by
contributing to tumor angiogenesis as well as by enhan-
cing tumor cell proliferation via TGF-β signaling.
Recently, it has been reported that Zinc finger E-box
binding homeobox 2 (ZEB2) fosters VM by TGF-β
induction of EMT in HCC where ZEB2 over-expression
significantly enhanced cell mobility and VM formation.
Up-regulation of ZEB2 increased VE-cadherin, VEFGR-2
and VEGFR-1 expression as well as MMP-2 and MMP-9
[67]. ZEB1 down-regulation decreased the expression of
VE-cadherin and VEGFR-2 in colorectal carcinoma,
which are characteristic of ECs. In conclusion, ZEB1
promote VM formation by inducing EMT in colorectal
carcinoma through the inhibition of VE-cadherin.
Other protein that has been identified to have a promin-
ent role in EMT is Twist1. This protein binds DNA using
similar E-box sequence motifs repressing E-cadherin and
up-regulating mesenchymal markers expression; over-ex-
pression of Twist1 significantly enhanced cell mobil-
ity, invasiveness and promoted VM formation in
HepG2 cells while chromatin immunoprecipitation
showed that Twist1 binds to the VE-cadherin pro-
moter and enhances its activity [68].
Cyclic adenosine monophosphate (cAMP)
cAMP is an essential second messenger involved in a
number of cellular processes, such as cell growth and
differentiation. It has also been linked to VM in cancer
[69, 70]. Firstly, a rise in cAMP levels reduced VM in
cutaneous and uveal melanoma. This inhibition appeared
to be dependent mostly on the exchange protein directly
activated by cAMP (Epac), but not on protein kinase A.
Secondly, VM impairment was associated with an inhib-
ition of ERK and PI3K/Akt signaling [70, 71], both of
which were previously mentioned as important partici-
pants in the vascular pathways.
Apart from vascular signaling, cAMP may be involved
in Notch signaling during endothelium development, so
there might be an association with VM, too. The exact
relationship between cAMP and Notch in endothelial
cell differentiation remains unknown, but cAMP has
been shown to modulate presenilin-1 (a component of
γ-secretase) in neurons [72].
Besides the different signaling described above other
key elements regulating VM are presented in Table 2.
Table 2 VM inducer and suppressor molecules
VM inducers References
HIF1α [50]
Twist1 [14]
Nodal [45]
Wnt5a [61]
VE-cadherin [111]
EphA2 [35]
Laminin 5γ2 [39]
CD133 [116]
VEGFR-1/2/3 [25]
[31]
[118]
PECAM1 [133]
Desmoglein 2 [134]
VM suppressors
FAK-related nonkinase [133]
PEDF [135]
cAMP [71]
TIMP-2 [136]
AP-2α [133]
miR-26b (EphA2) [137]
miR-200a (EphA2) [138]
miR-1236 (PI3K) [139]
miR-27a-3p (VE-cadherin) [140]
miR186 (Twist1) [141]
hsa-mir-299–5p [142]
miR-409-3p [143]
miR-124 [144]
[145]
miR-Let-7f [146]
Delgado-Bellido et al. Molecular Cancer  (2017) 16:65 Page 7 of 14
Vasculogenic mimicry and tumor
microenvironment
For a long time, it has been assumed that tumor micro-
environment (TME) plays an important role in develop-
ment and progression of tumors, including invasion and
metastasis [73, 74]. This physico-chemical niche includes
stromal cells and fibroblasts, blood vessels and oxygen
availability, immune cells, extracellular matrix (ECM),
and cytokines [75]. Both, TME and tumor, present a
bidirectional interaction that regulates several pro-
cesses in tumor progression. One if these regulated
processes is VM.
The first evidence of the influence of TME in VM was
proposed by Hendrix et al. in 2002 [76]. They induced
ischemic environment by surgery of the femoral artery
in nude mice and inoculated highly and poorly aggres-
sive human melanoma cells. They observed that highly
aggressive cells, but not poorly aggressive, overlapped
with endothelial cells in vasculogenesis of ischemic
muscle. They also found by immunohistochemistry that
only highly aggressive melanoma cells, but not control
cells, strongly expressed Notch-3 and Notch-4 [76]. In a
different study, they demonstrated that aggressive
melanoma cells can modify the ECM and reprogram the
poorly aggressive ones and inducing VM. Microarray
analysis confirmed differential gene expression in poorly
aggressive melanoma cells preconditioned with micro-
environment of aggressive melanoma cells. As mentioned
before, among up-regulated genes Eph2A, VE-Cadherin,
TIE-1, VEGF-C, metalloproteases (MMP) and γ2 chain of
laminin 5 (Ln5γ2) were present [77]. Cooperation between
endothelial cells and tumor cells in VM formation has also
been demonstrated in lung cancer [78]. Moreover,
aggressive melanoma cells but not poorly aggressive
melanoma cells induce VM in normal human mesen-
chymal stromal cells in co-culture. This effect is
mediated by VEGFA [79]. Treatment against aggres-
sive melanoma cells may ignore changes in ECM,
decreasing the effectiveness of the therapy.
Relationship between cancer-associated fibroblast
(CAFs) and VM has also been demonstrated. Conditioned
medium of CAFs induces VM in hepatic tumor cells in
vitro, and co-implantation of CAFs and hepatic tumor in
mouse xenografts showed an increase in VM formation
[80]. Additionally, CAFs were present among tumor cells
involved in VM formation. This effect is mediated by
paracrine effect of TGF-β and SDF1, which promote
VE-cadherin, MMP-2 and LAMC2 expression [80]. A
recent study demonstrates that TGF-β1 plays an essential
role to recruit bone marrow-derived mesenchymal stem
cells (MSC) to the tumor. TGF-β1 is involved in MSC
differentiation to CAFs which indeed develop VM.
Besides, MSC showed tropism with M2 macrophages, that
have been related to tumor aggressiveness [81].
Macrophages drill channels and promote microcircula-
tion in ischemic heart [82]. In a tumor context, macro-
phages have capacity of produce tubular network and
they have been also identified in VM formation. These
macrophages connect to blood vessels and express EMC
degrading proteases [83]. High number of infiltrated M2
macrophages have also been observed in GBM tumor
samples. These tumor associated macrophages induce
COX-2 dependent VM and their effect is inhibited by
Celecoxib [84].
Otherwise, conditioned medium from co-culture of
umbilical vein endothelial cells (HUVEC) and HTR-8
trophoblast cells in a three-dimensional system induces
VM in ovarian tumor cells (OVCAR-3). These results show
that chorionic gonadotropin (HCG) is essential in this in-
duction. HCG enhances HIF-1α and vascular markers.
Anti-HCG antibodies reverse this effect. However, siRNA
of HCG in OVCAR-3 do not inhibit VM, demonstrating
that this induction is due to microenvironment [85].
CSCs in vasculogenic mimicry
VM requires an adaptive response of tumor cells and
cellular “plasticity” is an essential property for this
purpose. Cancer Stem Cells (CSCs) are by definition the
tumor cell subpopulation with highest plasticity. In this
context, “plasticity” is defined as the capability of pluri-
potent CSCs for trans-differentiation.
In 1994, Lapidot et al. and Caceres-Cortes et al.
reported the first evidence of cancer initiating stem-like
cells by injection of different leukaemia cell subpopula-
tions in mice [86, 87]. Today CSCs have been deter-
mined in a wide range of solid tumors like breast
[88], gliomas [89], prostate [90], melanoma [91, 92], lung
[93, 94], colon [95–97], pancreatic [98], head and neck
squamous cell [99], liver [100], non-melanoma skin cancer
[101] and renal carcinoma [102].
CSCs represent an aggressive subpopulation of tumor
cells with capacity of self-renewal, multi-lineage differen-
tiation (stemness), tumor initiation and resistance of
radio- and chemotherapy [89, 103, 104]. CSCs pheno-
type is enhanced in perivascular niche of several tumors
and this correlates with aggressiveness [105, 106]. Further-
more, CSCs may trans-differentiate to ECs. This fact
demonstrates the implication of CSCs in vascularization
[107]. Also, several works have linked CSCs with VM
capacity in different tumor types. In triple-negative breast
cancer (TNBC), VM capacity statistically correlates with
CD133 CSCs marker expression [108], and this co-relation
was also demonstrated in other tumors like uveal and
cutaneous melanoma, gliomas, hepatocellular carcinoma
(HCC), non-small cell lung cancer (NSCLC) [108–110].
To have a global view of the importance of VM and its
interaction with CSCs we summarized above some key
findings linking these two aspects in different tumor types:
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Melanoma
Aggressive melanoma produces VM and it is inhibited
by down-regulation of VE-cadherin [111]. Melanoma
cancer stem cells (MCSCs) are identified by the expres-
sion of CD133 and ABCB5. These cells express VE-cad-
herin and they are located in the perivascular niche and
implicated in VM [112]. MCSCs also express VEGFR-1
and are required for VE-cadherin-dependent VM and
tumor growth [25]. Anti-VEGF treatments have been
proposed in the treatment of melanoma although with
low efficiency to target abnormal tumor angiogenesis,
due to the acquisition of anti-VEGF by VM induction.
This process is mediated by HIF-1α and involves MCSC
in perivascular niche [34]. It has also been reported that
PECAM1+/VEGFR-2– subpopulation of melanoma cells
induces VM in a PECAM1-dependent process. This
process is also dependent on AP-2α, a transcription fac-
tor that represses PECAM1 expression: while knock-
down of AP-2α up-regulates PECAM1 and promotes
tube formation, lentiviral re-introduction of AP-2α
down-regulates PECAM1 and inhibits tube formation
[113].
Gliomas
VM is proposed as an important target in glioblastoma
because abnormal vasculature induces the loss of
blood–brain barrier and contributes to brain edema
formation. The expression of VE-cadherin in glioblast-
oma stem-like cells (GSLCs) has been reported [114].
Based on this premise, Mao et al. demonstrated that
VE-cadherin is up-regulated under hypoxic conditions in
a way dependent on HIF-1α and HIF-2α and contributes
to hypoxia-induced VM [115]. In addition, GSLCs
express vascular endothelial growth factor receptor-2
(VEGFR-2) as well as other VM markers. shRNA for
VEGFR-2 inhibits tube-like structures formation, VM
and vascularization, but also self-renewal and tumor
xenograft initiation. For this reason, VEGFR-2 has been
proposed as an essential component for the maintenance
of stemness capacity and vascularization. VEGFR-2 is
necessary for the trans-differentiation of GCSCs to
mural cells [116–118]. Other stem-like cells implicated
in abnormal vasculogenesis of gliomas are endothelial
progenitor cells (EPCs). These cells are recruited from
bone marrow and contribute to tumor vascularization.
Strictly, EPCs are not tumoral but stem-like cells with
trans-differentiation capacity that contribute to tumors
aggressiveness [119].
Hepatocellular Carcinoma (HCC)
The transcription factor Twist1 is frequently expressed
in the nucleus of HCC cells. Up-regulation of Twist1
enhances VM and its knockdown prevents VM forma-
tion. Twist1 increases HCC cells plasticity by up-regulation
of VE-cadherin and down-regulation of E-cadherin [14].
Another report also suggests that Twist mediates hypoxia-
induced VM [48].
Mesenchymal phenotype and poor differentiation in
hepatocarcinoma correlates with VM acquisition. No
co-relation has been shown between expression of
stemness genes and intrinsic VM capacity and it has
been proposed that the role of stemness genes in VM
capacity of HCC cells is likely to depend on differen-
tiation status [120].
Non–small cell lung cancer (NSCLC)
In NSCLCs, a Hoechst 33342 dye effluxing side popula-
tion (SP) cells present features of CSCs. These cells
display tubular formation capacity in matrigel [121, 122].
The knockdown of Gli-l (a transcription factor that
positively regulates Sox2) by siRNA inhibits VM and
stemness capacities of SP cells [123]. YAP1 also regulates
the expression of Sox2 by physical interaction with
Oct4. NSCLC presents high levels of YAP1 and deple-
tion by knockdown reduces tubules formation capacity
in matrigel SP cells [124].
Breast cancer
Breast cancer stem cells (BCSCs) are identified by
CD24-, CD44+ and ALDH+ markers or mammosphere-
forming capacity. ALDH+, but not ALDH- cells, have
VM formation capacity in matrigel. Epidermal growth
factor (EGF) mediates this capacity and can be sup-
pressed by EGFR inhibitor gefitinib or shEGFR. Hsp27 is
downstream regulated by EGFR pathway and modulates
EGF-mediated VM capacity of BCSCs. Therefore, knock-
down of Hsp27 suppresses VM capacity of ALDH+ cells
[125]. Ubiquitin-specific protease 44 (UPS44) also
contributes to VM formation whereas UPS44 knock-
down inhibits VM formation of CSCs in vivo [126].
Targeting vasculogenic mimicry
As the use of anti-angiogenic therapies against tumor
development has had limited results there is a critical
need to attempt novel anti-tumor angiogenesis strategies
centered in targeting alternative mechanism used by the
tumor cells (by way of trans-differentiation) to become
pseudo-vascular cells leading to VM.
Numerous studies have attempted to specifically
disable VM in different tumor models (Table 3). In a
recent report our group has shown that the use of PARP
inhibitors was effective in preventing melanoma-derived
lung metastasis in a murine model and this effect was in
part explained by PARP inhibitor’s faculty to counteract
VM through down-regulation of VE-cadherin concomi-
tant to the loss of EMT attributes linked to a decreased
vimentin expression and Integrin-Linked Kinase/GSK3β
axis down-regulation [127].
Delgado-Bellido et al. Molecular Cancer  (2017) 16:65 Page 9 of 14
The Rho kinase inhibitors fasudil and Incarvin C have
also been shown to prevent VM of B16 mouse melanoma
cells and HCC in Matrigel and xenograft tumor growth as
therapeutic option for targeting cancer VM [128, 129]. An
interesting study by Orechia et al. [130] has shown the
syndecan-1 co-expression with VM markers in melanoma
patient cell lines having vasculogenic/stem-cell like
phenotype; melanoma cells lose their ability to form
tubule-like structures in vitro after blocking syndecan-1
activity by the specific human recombinant antibody,
OC-46 F2 while the combined therapy using OC-46 F2
and L19-IL2, led to a complete inhibition of tumor growth
until day 90 from tumor implantation in 71% of treated
mice [130].
Another example of VM targeting has used TNBC as
proof-of-concept. TNBC cells remaining after conven-
tional chemotherapy readily form VM, which leads to the
relapse of cancer after treatment. Functional liposomes
vincristine plus dasatinib modified by a targeting mol-
ecule DSPE-PEG2000-c(RGDyK), exhibited the super-
ior performances in the enhancement of cellular
uptake via targeted action and the induction of apop-
tosis and removal of VM channels in the TNBC-
bearing mice [131].
A similar approach has been reported for VM in
glioblastoma multiforme (GBM). Current prognosis of
GBM remains extremely poor attributed to the forma-
tion of VM and the presence of glioma initiating cells
(GICs) responsible for resistence to current therapies
and disease recurrence; paclitaxel-loaded liposomes
modified with a peptide R8-c(RGD) (R8-c(RGD)-Lip)
were used for the treatment of glioma [132]. An in vitro
cellular uptake study proved the strongest targeting abil-
ity to be that of R8-c(RGD)-Lip to glioma stem cells.
Drug loaded R8-c(RGD)-Lip exhibited an efficient anti-
proliferation effect on BCSCs and could induce the
destruction of VM channels in vitro. The pharmaco-
dynamics study demonstrated that R8-c(RGD)-modified
drug-loaded liposomes achieved both anti-VM and
anti-BCSC effects in vivo. Finally, no significant cytotox-
icity of the blood system or major organs of the drug-
loaded liposomes was observed under treatment dosage
in the safety evaluation. In conclusion, all of the results
proved that R8-c(RGD)-Lip was a safe and efficient
anti-glioma drug delivery system [132].
Conclusion
This review features on one specific strategy that tumor
cells utilize to escape from the hostile microenvironment
through trans-differentiation leading to a “caricature” of
endothelial-like cells, VM. This trans-differentiation
allows the tumor mass to evolve to an irrigated, avascu-
lar network to avoid shortage of nutrients and oxygen
inside the tumor. As we have reviewed, this phenotype
change is pertinent to aggressive metastatic behavior
and has functional and translational relevance. The
molecular pathways underlying VM have lighted up VE-
cadherin as a critical component of VM and, therefore it
needs to be taken into account for the development of
innovative treatment strategies that target tumor cell
plasticity and the metastatic properties affiliated with
disease recurrence and drug resistance. As a prominent
future challenge, new concepts are needed to discern the
specific signaling peculiarities of VE-cadherin (different
from its role in the endothelial context) affecting tumor
cell biology and related to VM/aggressive development.
Particular attention is needed to identify the precursors
of tumor cells committed to acquire VE-cadherin
expression/VM phenotype and to the interactome
connecting VE-cadherin with cell trans-differentiation.
In this regard, the presence of elevated levels of nuclear
VE-cadherin and phospho-VE-cadherin in VM-prone
cells (unpublished results) could be crucial to under-
stand the specific role non vascular VE-cadherin in the
acquisition of invasive properties. Our ability to effect-
ively abolish cancer is limited in part by the diverse
Table 3 Pharmacological agents targeting VM
Therapeutic agents Molecular target or function Effect on VM References
Bevacizumab (Avastin) VEGF no effect [114]
PARP inhibition VE-cadherin inhibition [127]
Thalidomide (Thalomid) TNFα; ROS producer inhibition [147]
TNP-470 (AGM-1470) TK inhibition no effect [148]
Endostatin (rhEndostatin, Endostar) integrin signaling no effect [149]
Rapamycin (Rapamune) mTOR, VEGF inhibition [150]
Curcumin EPHA2, PI3K, MMPs inhibition [151]
Isoxanthohumol TGF-β signaling inhibition [152]
Vadimezan (ASA404, AS1404, DMXAA) MAPK, VE-cadherin inhibition [140]
Resveratrol VEGF-R1, VEGF-R2 inhibition [153]
Ginsenoside Rg3 VE-cadherin/MMPs/EPHA2 inhibition [154]
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vasculature development in relation with heterogeneous
subpopulations contributing to tumors. Moreover, the
unintended consequences of hypoxia induced by rapid
tumor growth or by some conventional therapies may
serve as a catalyst for the VM and CSCs phenotype.
Through a profound elucidation of VM biology these
limitations could be override. Therefore, it seems
prudent, and definitely appropriate, to consider the ap-
plication of new agents to target VM pathways associ-
ated with the stem cell phenotype and resistant to most
conventional agents. Targeting VM with specific molecu-
lar compounds used in a combinatorial manner with
front-line therapies may hold the greatest promise in the
war on cancer.
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